Brandywine Global Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Brandywine Global Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-414,084	Closed	-$2.51M	–	700
2023 Q4	$2.51M	Sell	414,084 -43,250	-9%	-$193K	0.02%	519
2023 Q3	$1.93M	Buy	457,334 +55,654	+14%	+$208K	0.02%	553
2023 Q2	$1.25M	Buy	+401,680	New	+$856K	0.01%	607
2022 Q4	–	Sell	-188,559	Closed	-$381K	–	724
2022 Q3	$381K	Sell	188,559 -9,083	-5%	-$25.5K	﹤0.01%	687
2022 Q2	$629K	Sell	197,642 -10,825	-5%	-$39.2K	0.01%	649
2022 Q1	$869K	Buy	208,467 +11,744	+6%	+$52K	0.01%	633
2021 Q4	$942K	Hold	196,723	–	–	0.01%	585
2021 Q3	$1.05M	Buy	196,723 +25,808	+15%	+$130K	0.01%	570
2021 Q2	$875K	Sell	170,915 -4,898	-3%	-$27.8K	0.01%	576
2021 Q1	$1.18M	Sell	175,813 -9,375	-5%	-$52K	0.01%	553
2020 Q4	$846K	Buy	+185,188	New	+$821K	0.01%	533

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brandywine Global Investment Management's AMRX Position: Q1 2024 in Review

Brandywine Global Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2024, closing a stake of 414,084 shares — an estimated $2.51M sold.

Brandywine Global Investment Management first reported a position in AMRX in Q4 2020 and held it in 11 quarters. The position peaked at $2.51M in Q4 2023. 175 funds tracked by Wall St. Rank hold AMRX as of Q1 2024.

Brandywine Global Investment Management reported no remaining Amneal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Brandywine Global Investment Management sold 414,084 Amneal Pharmaceuticals shares in Q1 2024, an estimated $2.51M.
Brandywine Global Investment Management first reported a position in Amneal Pharmaceuticals in Q4 2020 and held it in 11 quarters.
Brandywine Global Investment Management's Amneal Pharmaceuticals position peaked at $2.51M in Q4 2023.
175 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2024.

Based on Brandywine Global Investment Management's 13F filing for Q1 2024, filed 13 May 2024.